Unichem Laboratories Limited (UNICHEMLAB.NS)
INR 746.9
(-1.82%)
INR 746.9
(-1.82%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.47 Billion INR | -21.19% |
| 2022 | 3.14 Billion INR | -10.05% |
| 2021 | 3.49 Billion INR | 193.18% |
| 2020 | 1.19 Billion INR | -42.33% |
| 2019 | 2.06 Billion INR | 3.43% |
| 2018 | 1.99 Billion INR | 32.47% |
| 2017 | 1.5 Billion INR | 53.71% |
| 2016 | 980.59 Million INR | 172.68% |
| 2015 | 359.61 Million INR | 63.67% |
| 2014 | 219.71 Million INR | -14.45% |
| 2013 | 256.83 Million INR | -5.1% |
| 2012 | 270.64 Million INR | -60.99% |
| 2011 | 693.76 Million INR | 38.69% |
| 2010 | 500.22 Million INR | 39.82% |
| 2009 | 357.77 Million INR | -9.95% |
| 2008 | 397.31 Million INR | 63.36% |
| 2007 | 243.21 Million INR | -7.66% |
| 2006 | 263.38 Million INR | -10.23% |
| 2005 | 293.4 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 2.47 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 2.47 Billion INR | -21.19% |
| 2023 Q2 | 2.9 Billion INR | 0.0% |
| 2022 Q4 | 3.14 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 3.1 Billion INR | 0.0% |
| 2022 FY | 3.14 Billion INR | -10.05% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 2.73 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 3.49 Billion INR | 0.0% |
| 2021 FY | 3.49 Billion INR | 193.18% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 1.19 Billion INR | -42.33% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 1.74 Billion INR | 0.0% |
| 2020 Q4 | 1.19 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 2.06 Billion INR | 3.43% |
| 2019 Q4 | 2.06 Billion INR | 0.0% |
| 2019 Q2 | 2.1 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 FY | 1.99 Billion INR | 32.47% |
| 2018 Q4 | 1.99 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q3 | 2.06 Billion INR | 0.0% |
| 2017 FY | 1.5 Billion INR | 53.71% |
| 2017 Q4 | 1.5 Billion INR | -27.09% |
| 2016 FY | 980.59 Million INR | 172.68% |
| 2016 Q4 | 980.59 Million INR | 0.0% |
| 2015 FY | 359.61 Million INR | 63.67% |
| 2014 FY | 219.71 Million INR | -14.45% |
| 2013 FY | 256.83 Million INR | -5.1% |
| 2012 FY | 270.64 Million INR | -60.99% |
| 2011 FY | 693.76 Million INR | 38.69% |
| 2010 FY | 500.22 Million INR | 39.82% |
| 2009 FY | 357.77 Million INR | -9.95% |
| 2008 FY | 397.31 Million INR | 63.36% |
| 2007 FY | 243.21 Million INR | -7.66% |
| 2006 FY | 263.38 Million INR | -10.23% |
| 2005 FY | 293.4 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 1.43 Billion INR | -73.024% |
| Ind-Swift Limited | 10.13 Billion INR | 75.59% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 25.632% |
| Sakar Healthcare Limited | 793.51 Million INR | -211.921% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 96.277% |
| Innova Captab Limited | 2.45 Billion INR | -0.983% |
| Divi's Laboratories Limited | 30 Million INR | -8150.473% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -5282.85% |
| Morepen Laboratories Limited | 289.99 Million INR | -753.521% |
| Mankind Pharma Limited | 2.07 Billion INR | -19.473% |
| Sequent Scientific Limited | 4.87 Billion INR | 49.248% |
| Wanbury Limited | 1.16 Billion INR | -112.487% |
| Laurus Labs Limited | 25.77 Billion INR | 90.397% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 61.054% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -1343.4% |
| Alembic Limited | 91.5 Million INR | -2605.073% |
| Hikal Limited | 8.17 Billion INR | 69.726% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 51.767% |
| Neuland Laboratories Limited | 953.89 Million INR | -159.477% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 34.461% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 79.892% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -655.538% |
| Themis Medicare Limited | 957.92 Million INR | -158.387% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 69.222% |
| Lupin Limited | 29.21 Billion INR | 91.529% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -14221.252% |
| Wockhardt Limited | 23.56 Billion INR | 89.494% |
| Vaishali Pharma Limited | 134.91 Million INR | -1734.553% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 13.229% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -2668.306% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 93.245% |
| FDC Limited | 205.18 Million INR | -1106.298% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 87.637% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -682.122% |
| Eris Lifesciences Limited | 27.81 Billion INR | 91.101% |
| Venus Remedies Limited | 413.3 Million INR | -498.873% |
| ZIM Laboratories Limited | 1.08 Billion INR | -127.444% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -147.911% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -12464.173% |
| Shilpa Medicare Limited | 9.37 Billion INR | 73.595% |
| Albert David Limited | 33.24 Million INR | -7345.828% |
| Ajanta Pharma Limited | 352.8 Million INR | -601.571% |
| Hester Biosciences Limited | 2.44 Billion INR | -1.283% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -280.812% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 75.53% |
| Gufic Biosciences Limited | 3.32 Billion INR | 25.653% |
| Windlas Biotech Limited | 36.41 Million INR | -6697.973% |
| Procter & Gamble Health Limited | 95.6 Million INR | -2489.061% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | -689.461% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -151.303% |
| Granules India Limited | 13.15 Billion INR | 81.179% |
| Aarti Drugs Limited | 5.64 Billion INR | 56.136% |
| Bal Pharma Limited | 1.39 Billion INR | -77.241% |
| Alkem Laboratories Limited | 14.18 Billion INR | 82.55% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 92.439% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -23101.556% |
| Medicamen Biotech Limited | 308.17 Million INR | -703.169% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | -914.847% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -56294.213% |
| Valiant Laboratories Limited | 767.08 Million INR | -222.669% |
| Orchid Pharma Limited | 1.35 Billion INR | -83.099% |
| Medico Remedies Limited | 80.5 Million INR | -2974.558% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -1389.112% |
| Ipca Laboratories Limited | 14.38 Billion INR | 82.792% |
| Brooks Laboratories Limited | 56.41 Million INR | -4287.072% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -241.462% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.538% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 93.846% |
| NATCO Pharma Limited | 3.71 Billion INR | 33.321% |
| Suven Life Sciences Limited | 7.09 Million INR | -34775.891% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -27.961% |
| Strides Pharma Science Limited | 25.16 Billion INR | 90.166% |
| Indoco Remedies Limited | 6.71 Billion INR | 63.165% |
| Alpa Laboratories Limited | 52.46 Million INR | -4617.701% |
| Lasa Supergenerics Limited | 220.76 Million INR | -1021.181% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -304.766% |